ArticleRenal failure2025
Characteristics of adult membranous nephropathy patients with capillary co-deposition of IgG and IgA.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembranous nephropathy (MN) is characterized by subepithelial immune complex deposits of IgG, particularly anti-Phospholipase A2 Receptor (anti-Pla2r). However, presence of IgA co-deposition along subepithelial region of the glomerular capillary walls has not been extensively investigated.
methodsFive hundred thirty-one biopsy-proven MN patients from Huashan Hospital were screened for capillary IgA deposition. Clinical, biological and histopathological data were collected at biopsy and during follow-ups. A propensity score matched cohort was used to compare treatment response and outcomes between MN patients with capillary co-deposition of IgG and IgA (cIgA-MN) and MN without. Immunofluorescence was used to detect IgA, IgG, Galactose deficient-IgA1 (Gd-IgA1) and Pla2r deposition. ELISA was performed to measure circulating Gd-IgA1 level. IgA and IgG subtypes of sera anti-Pla2r antibodies were investigated by indirect immunofluorescence and validated by ELISA.
resultsFifty-three of 531 MN patients exhibited capillary IgA co-deposition with IgG. Secondary causes were identified in 19 of 53 cIgA-MN patients. The remaining 34 primary cIgA-MN patients had median proteinuria of 6.1 g/day and showed no crescents and mild endocapillary proliferation. 73.5% cIgA-MN patients were positive for Pla2r. Gd-IgA1 was absent in glomeruli of cIgA-MN patients and circulating Gd-IgA1 levels were similar to those in MN patients without IgA deposition. Meanwhile, circulating IgA-type anti-Pla2r antibodies were detected in a subset of cIgA-MN patients. Outcome analysis revealed comparable remission rates and progression to end-stage kideny disease between cIgA-MN and MN without IgA deposition.
conclusionThis study highlights clinical and pathological features of cIgA-MN, suggesting complex immune responses involving IgA in MN. IgA co-deposition did not significantly alter treatment responses or long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.